Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gsk-461364. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 known ✓ | P53350 | 18/20 | 1.00 |
| ▸ | PLK3 | Q9H4B4 | 11/20 | 1.00 |
| ▸ | NEK2 | P51955 | 3/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 2/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 2/20 | 1.00 |
| ▸ | PIM1 | P11309 | 2/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 2/20 | 1.00 |
| ▸ | PIK3C2B | O00750 | 1/20 | 1.00 |
| ▸ | RIOK3 | O14730 | 1/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 1/20 | 1.00 |
| ▸ | PIP5K1C | O60331 | 1/20 | 1.00 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | KIT | P10721 | 1/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 1.00 |
| ▸ | GRK4 | P32298 | 1/20 | 1.00 |
| ▸ | TIE1 | P35590 | 1/20 | 1.00 |
| ▸ | FLT3 | P36888 | 1/20 | 1.00 |
| ▸ | PRKCI | P41743 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gsk-461364 SCHEMBL29360650 | 1.00 | PLK1 (1.00) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| Gsk-461364 SCHEMBL4276841 | 1.00 | PLK1 (1.00) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| Gsk-461364 SCHEMBL29655945 | 1.00 | PLK1 (1.00) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| SCHEMBL19196385 | 0.95 | PLK1 (0.91) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| SCHEMBL25660820 | 0.94 | PLK1 (0.89) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| SCHEMBL2973906 | 0.94 | PLK1 (0.88) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| SCHEMBL2973537 | 0.92 | PLK1 (0.86) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| SCHEMBL4562944 | 0.92 | PLK1 (0.86) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| SCHEMBL4405982 | 0.92 | PLK1 (0.86) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| SCHEMBL13573235 | 0.92 | PLK1 (0.86) | PLK1PLK3NEK2PIK3CDPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630532-B2 | Indole-substituted quinolines and their combination with Plk1 inhibitors for the treatment of cancer | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2026-05-19 | — | — | US | claimed |
| CN-122005814-A | Drug-loaded polymer micelle, gel drug system, preparation method and application | 苏州大学 | 2026-05-12 | — | — | CN | claimed |
| CN-122005552-A | Medicine for improving expression of lysosomal related transmembrane protein 4B and screening method thereof | 安徽医科大学 | 2026-05-12 | — | — | CN | claimed |
| US-20260092327-A1 | METHODS OF MONITORING MUTATIONS IN TREATMENT OF COLORECTAL CANCER | CARDIFF ONCOLOGY INC (US) | 2026-04-02 | — | — | US | claimed |
| US-20260076970-A1 | CANCER TREATMENT USING MTDP INHIBITORS AND PLK1 INHIBITORS | CARDIFF ONCOLOGY INC (US) | 2026-03-19 | — | — | US | claimed |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4704832-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Biohaven Therapeutics Ltd. (VG) | 2026-03-11 | — | — | EP | claimed |
| EP-4048260-B1 | COMBINATION OF SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR USE IN TREATING A HEMATOLOGICAL MALIGNANCY | CELGENE CORP (US) | 2026-03-11 | — | — | EP | claimed |
| US-20260022117-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | ARVINAS OPERATIONS INC (US) | 2026-01-22 | — | — | US | claimed |
| US-12485178-B2 | Bifunctional small molecules to target the selective degradation of circulating proteins | YALE UNIVERSITY (US) | 2025-12-02 | — | — | US | claimed |
| WO-2022055721-A1 | SELECTION AND TREATMENT OF CANCER WITH COMBINATION THERAPIES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-03-17 | — | — | WO | claimed |
| CN-114096280-A | Therapeutic constructs for co-delivery of mitotic kinase inhibitors and immune checkpoint inhibitors | 俄勒冈健康与科学大学 | 2022-02-25 | — | — | CN | claimed |
| US-20220054496-A1 | MODULATION OF TRF1 FOR BRAIN CANCER TREATMENT | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) | 2022-02-24 | — | — | US | claimed |
| EP-3946313-A1 | PLK1 INHIBITORS AND PSA LEVELS IN PROSTATE CANCER | Cardiff Oncology, Inc. (US) | 2022-02-09 | — | — | EP | claimed |
| US-20180369214-A1 | Methods of Diagnosing and Treating Small Cell Lung Cancer Using Polo-Like Kinase 1 (PLK1) Inhibitors | EMORY UNIVERSITY | 2018-12-27 | — | — | US | claimed |
| US-8236954-B2 | Processes for preparing benzimidazole thiophenes | GLAXOSMITHKLINE LLC (US) | 2012-08-07 | — | — | US | claimed |
| US-20100256376-A1 | Processes For Preparing Benzimidazole Thiophenes | GLAXOSMITHKLINE LLC | 2010-10-07 | — | — | US | claimed |
| EP-2170871-A2 | PROCESSES FOR PREPARING BENZIMIDAZOLE THIOPHENES | GlaxoSmithKline LLC (US) | 2010-04-07 | — | — | EP | claimed |
| WO-2009151914-A1 | METHODS FOR TREATING NEOPLASMS WITH A COMBINATION OF A PLK INHIBITOR AND RETINOID | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-17 | — | — | WO | claimed |
| WO-2009002916-A2 | PROCESSES FOR PREPARING BENZIMIDAZOLE THIOPHENES | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076970-A1 | CANCER TREATMENT USING MTDP INHIBITORS AND PLK1 INHIBITORS | PLK1, PLK4, PLK2 | PLK1 1/4885PLK3 7/4885NEK2 35/4885 |
| US-20260022117-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | VHL, ADRM1, MDM2 | PLK1 848/4885PLK3 2166/4885NEK2 2229/4885 |
| US-12485178-B2 | Bifunctional small molecules to target the selective degradation of circulating proteins | ASGR1, LDLR, FCGR2A | PLK1 2897/4885PLK3 3156/4885NEK2 4784/4885 |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | MDM2, UBR4, UBE3A | PLK1 291/4885PLK3 2039/4885NEK2 2665/4885 |
| US-20100256376-A1 | Processes For Preparing Benzimidazole Thiophenes | TPMT, TBKBP1, TYMP | PLK1 735/4885PLK3 982/4885NEK2 774/4885 |
| US-20260092327-A1 | METHODS OF MONITORING MUTATIONS IN TREATMENT OF COLORECTAL CANCER | KRAS, HRAS, NRAS | PLK1 25/4885PLK3 103/4885NEK2 12/4885 |
| US-20220054496-A1 | MODULATION OF TRF1 FOR BRAIN CANCER TREATMENT | ERBB3, ERBB2, HSP90AB1 | PLK1 242/4885PLK3 1130/4885NEK2 971/4885 |
| US-12630532-B2 | Indole-substituted quinolines and their combination with Plk1 inhibitors for the treatment of cancer | PLK1, MYC, PLK4 | PLK1 1/4885PLK3 10/4885NEK2 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.